Mechanism of Action
Guanylate Cyclase-C Activation
Linaclotide binds and activates the guanylate cyclase-C (GCC) receptor on intestinal epithelial cells. This increases intracellular cGMP, which activates CFTR chloride channels and inhibits sodium-hydrogen exchangers. The result is chloride, bicarbonate, and water secretion into the intestinal lumen, softening stool and accelerating transit.
Visceral Pain Reduction
At doses used for IBS-C, linaclotide reduces visceral hypersensitivity. Elevated intracellular cGMP activates PKGII, which inhibits nociceptive nerve fiber activity via paracrine signaling. This analgesic effect on colonic afferents is separate from the secretory mechanism and explains symptom relief beyond constipation.
Research Summary
IBS-C Clinical Trials
FDA ApprovedPhase 3 trials in IBS-C demonstrated that linaclotide 290 mcg significantly improved abdominal pain, bowel movement frequency, and stool consistency versus placebo. Approximately 34% of patients met the composite responder endpoint versus 14% on placebo. Effects were maintained over 26-week treatment periods.
Chronic Idiopathic Constipation
FDA ApprovedIn CIC trials, linaclotide 72 mcg and 145 mcg doses significantly increased complete spontaneous bowel movements and reduced straining and stool consistency scores. The lower dose is approved for CIC given the absence of a significant pain component requiring higher dosing.
Calculate your Linaclotide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| IBS-C treatment | 290 mcg | Once daily | Oral, 30 min before first meal |
| Chronic idiopathic constipation | 72-145 mcg | Once daily | Oral, 30 min before first meal |
Contraindicated in pediatric patients under 6 years. Pediatric deaths from fluid loss reported in younger children.
Interactions
Safety Profile
The most common adverse effect is diarrhea (20% of patients), which is dose-dependent. Severe diarrhea leading to discontinuation occurs in approximately 2% of patients. Linaclotide is contraindicated in pediatric patients under 6 years due to risk of serious dehydration. Systemic exposure is minimal (<1%), reducing systemic adverse effects. No significant drug interactions due to local mechanism of action.
References
- [1]Chey WD et al. (2012). Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. American Journal of Gastroenterology, 107(11), 1702-1712.
- [2]Lembo AJ et al. (2010). Linaclotide is associated with improvements in abdominal pain and bowel habits in adults with irritable bowel syndrome with constipation: results of a phase 2b trial. Gut, 59(11), 1497-1506.